ESTRO-EORTC expert guideline on target delineation and radiotherapy details for stage I-III small cell lung cancer

Stage I-III limited-stage small cell lung cancer (SCLC) is a highly aggressive yet potentially curable disease with concurrent chemoradiotherapy. Thoracic radiation therapy (RT) plays a central role in the management of stage I-III SCLC; however significant variation exists in staging, target volume delineation, dose prescription, and integration with systemic therapy. This document provides an updated European recommendations on the use of RT in stage I-III SCLC, reflecting recent evidence and advancements in clinical practice.